The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2)

Lalitha Nayak, Hong Shi, G. Brandon Atkins, Zhiyong Lin, Alvin H. Schmaier, Mukesh K. Jain

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Multiple myeloma confers a high risk for vascular thrombosis, a risk that is increased by treatment with immunomodulatory agents. Strikingly, inclusion of the proteasome inhibitor bortezomib reduces thrombotic risk, yet the molecular basis for this observation remains unknown. Here, we show that bortezomib prolongs thrombosis times in the carotid artery photochemical injury assay in normal mice. Cell-based studies show that bortezomib increases expression of the transcription factor Kruppel-like factor 2 (KLF2) in multiple cell types. Global postnatal overexpression of KLF2 (GL-K2-TG) increased time to thrombosis, and global postnatal deletion of KLF2 (GL-K2-KO) conferred an antiparallel effect. Finally, studies in GL-K2-KO mice showed that the thromboprotective effect of bortezomib is KLF2 dependent. These findings identify a transcriptional basis for the antithrombotic effects of bortezomib.

Original languageEnglish (US)
Pages (from-to)3828-3831
Number of pages4
JournalBlood
Volume123
Issue number24
DOIs
StatePublished - Jun 12 2014

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2)'. Together they form a unique fingerprint.

  • Cite this